OUR PORTFOLIO

Anaveon is a clinical-stage biopharmaceutical company, based in Switzerland, that develops biologics to modulate the function of cytokines and provide substantial therapeutic benefit to cancer patients. Our vision is to develop novel immune therapies benefiting patients suffering from a wide variety of diseases with immune pathology.

Anjarium Biosciences, strives to create and deliver solutions for patients beyond what current gene therapy platforms address today. Anjarium is developing a new generation of genetic medicines to overcome the greatest challenges facing the field, notably immunogenicity, payload capacity, individualized multiple dosing, targeted delivery and scaled manufacturing.

Autobahn is a biotechnology company developing a pipeline of transformative small molecule therapies for the treatment of CNS disorders. The company’s lead program leverages a brain-targeting chemistry platform to target the unambiguous link between thyroid hormone and myelin biology for AMN and MS.

BioGraph 55 is an immuno-oncology target discovery and drug development company that uses advanced imaging analytics and machine learning to capture clinically relevant content from the tumor microenvironment.

Capstan is combining the power of in vivo cell therapy with the precision of genetic medicines to develop new treatment options for patients across oncology, fibrosis, inflammation-related diseases, and monogenic blood disorders. Our founders include inventors of the first clinically approved CAR-T and of lipid nanoparticles that are enabling mRNA medicines.

DEM Bio is pioneering the next generation of immunotherapeutics designed to unleash macrophages and other myeloid effector cells to eliminate tumors by targeting novel ‘don’t eat me’ (DEM) and ‘eat me’ (EM) signals on cancer cells and macrophages. Our company’s proprietary CHoMP™ platform (Co-culture with Human Myeloid Phagocytes) will be used to identify unexplored DEM and EM signals in a systematic and unbiased manner via inter-cellular CRISPR screening using tumor cells, primary macrophages, and other innate immune effector cells. DEM Bio was co-founded by Longwood Fund and distinguished scientists Drs. Jonathan Weissman, Kipp Weiskopf, and Michael Bassik.

EvolveImmune is rapidly transforming the discovery and development of novel immunotherapies. By leveraging its proprietary in vivo target discovery platform, EvolveImmune is building a pipeline of novel therapeutic candidates against numerous targets which are expressed on multiple immune cell types, with the aim to generate first-in-class treatments for unmet needs in oncology and autoimmune diseases.

FoRx is developing first-in-class small-molecule therapeutics that exploit the presence of DNA replication stress in human cancers.

Interius BioTherapeutics is an early-stage biotechnology company initially focused on treating hematologic malignancies by leveraging its platform to generate chimeric antigen receptor (CAR) T cells directly in vivo. Our unique therapeutic approach bypasses the need for ex vivo cell manipulations and the potentially toxic pre-conditioning chemotherapy required for standard CAR T-cell treatments.  The company is also developing applications beyond immuno-oncology that address diseases not amenable to current gene therapy modalities.

Jnana Therapeutics is building the first small molecule drug discovery platform dedicated to SLC transporters, an ancient membrane protein family thought to be relevant in a wide range of diseases. Jnana’s proprietary chemistry and biology platform allows the company to rapidly and comprehensively address therapeutic targets across the SLC family, with an initial focus on immuno-oncology, inflammatory disorders, and neurological diseases.

Kestrel is discovering and developing new molecules to treat intractable cancers.

We are starting with potent inhibitors of pan-oncogenic-RAS.

We rely on exceptional science, and our focus, always, is on patients.

Levicept is an asset-centric UK-based biotechnology company developing a novel, safe and efficacious biological therapy (LEVI-04 [p75NTR-Fc]) for the treatment of chronic pain.

Mediar is a preclinical stage biotechnology company developing therapeutics to halt, or even reverse, fibrosis. The platform and pipeline are based on an emerging class of novel targets – fibrotic mediators – that play key roles in modulating myofibroblast biology and the development of fibrosis in chronically damaged organs.

MindImmune Therapeutics is a preclinical stage biotech company developing first-in-class drugs that target the immune system to treat CNS diseases. The company is at the forefront of biological advances linking the peripheral immune system to neuroinflammation.

Nucleome Therapeutics is decoding the disease-linked variants located in the dark matter of the human genome to discover first-in-class precision medicine. Nucleome’s platform combines pioneering 3D genome technology and machine learning to shed light on these variants by directly linking genes

Parthenon Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is relevant in drug development as many cancers use the TME to build barriers that shield immune system attack. One approach, PRTH-101, breaks these barriers to overcome recalcitrant cancers.

PrescriberPoint is transforming the way pharmaceutical companies interact with healthcare providers. The company is creating a digital marketplace based on a “pull” vs. “push” model where healthcare providers can access all the support they need from Pharmacos on their terms, industry-wide, in one place including access to product information, samples, rep and MSL support and patient assistance programs.

ReCode is developing a proprietary non-viral Selective ORgan Targeting (SORT) LNP technology with lead indications in the rare pulmonary diseases of primary ciliary dyskinesia (PCD) and cystic fibrosis (CF). The SORT platform, which enables precise organ targeting of payloads via both systemic and local delivery, is compatible with a variety of payloads (mRNA, siRNA, DNA, small molecule), including mixed cargos such as RNA/protein complexes for gene editing.

RESILIENCE is a first-of-its-kind manufacturing and technology company dedicated to broadening access to complex medicines and protecting biopharmaceutical supply chains against disruption. Founded in 2020, the company is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the medicines of today and tomorrow can be made quickly, safely, and at scale.

Saama is an AI-driven Intelligent Clinical Cloud company, enabling the life sciences industry to conduct faster and safer clinical development and regulatory programs.  Their Life Science Analytics Cloud (LSAC) platform is used by many biopharmaceutical companies on thousands of studies.   LSAC’s rich applications facilitate an unprecedented, authoritative oversight of comprehensive clinical research data, enabling companies to file New Drug Applications (NDAs) more efficiently and bring drugs to market faster. 

Simcha Therapeutics is an early stage biopharmaceutical company with a focus on developing next generation cytokine immunotherapies to trigger the immune system to fight disease, particularly cancers. The company was incorporated in 2018 and is based in New Haven, Connecticut.

TRex Bio is a stealth mode, discovery-stage biotechnology company focused on making a meaningful difference in the lives of patients suffering from fatal or debilitating illnesses including cancer, fibrotic, autoimmune and inflammatory diseases. TRex aims to achieve this vision via functional manipulation of Tregs and other immune cells in a tissue-specific and disease-specific fashion.

TRIANA Biomedicines is developing molecular glue therapeutics initially tailored for targeted protein degradation applications. TRIANA is building its pipeline using a target-first, rational approach to molecular glue discovery, and aspires to develop products for a wide range of therapeutic applications.

VitaDAO is a DAO collective for community-governed and decentralized drug development. Our core mission is the acceleration of research and development (R&D) in the longevity space and the extension of human life and healthspan.

4D Molecular Therapeutics is a gene therapy company with a transformative discovery platform – Therapeutic Vector Evolution – that enables invention of optimized and proprietary AAV vectors, each specifically designed to deliver genes to specific cells and tissues in the body, allowing treatment of diseases with high unmet medical needs. The company is currently focused on rare diseases of the eye, heart, muscle and lung.

Ablexis’ AlivaMab™ Mouse technology, a world-class transgenic mouse platform, is being developed to provide the foundation for the efficient discovery and development of the next wave of human therapeutic antibodies to treat human diseases. Ablexis will commercialize the AlivaMab™ Mouse platform through creative partnering strategies.

Accelerator New York is a leading life science investment vehicle supporting emerging biotechnology research. Accelerator will infuse strategic venture capital, entrepreneurial leadership, and critical product development capabilities into the New York City life science cluster. Accelerator NY is located at the Alexandria Center for Life Science in the heart of Manhattan’s East Side Medical Corridor.

Aquinox is developing novel small molecule therapeutics for the treatment of cancer and inflammatory disease. The primary focus is anti-inflammatory product candidates targeting SH2-containing inositol 5'-phosphatase (known as SHIP1), which plays an important role in the PI3K cellular signaling pathway in immune cells. Rosiptor, (AQX-1125), Aquinox’s lead candidate, is in a Phase 3 trial of interstitial cystitis / bladder pain syndrome (IC/BPS).

BioAtla develops novel monoclonal antibody and cell-based immunotherapies with improved therapeutic index for the treatment of cancer. The company’s proprietary platforms include Conditionally Active Biologics and Comprehensive Integrated Antibody Optimization that enable biologics with more selective targeting of cancer tissue and improved manufacturability.

BioNTech was founded in 2008 on the understanding that every cancer patient’s tumor is unique and therefore each patient’s treatment should be individualized. Its cutting-edge pipeline includes individualized mRNA-based product candidates, innovative chimeric antigen receptor T cells, novel checkpoint immunomodulators, targeted cancer antibodies and small molecules.

BlueLight Therapeutics is a biotechnology company that uses a novel structure-function-based approach to develop new therapeutic molecules against challenging drug targets to treat a wide range of serious diseases.

Bolt is a clinical-stage biotechnology company developing its Immune-Stimulating Antibody Conjugate (ISAC) platform technology to harness the power of the innate immune system to treat cancer. The company’s lead ISAC is delivered systemically as monotherapy for HER2-expressing cancers.

Complexa is a clinical stage biopharmaceutical company focused on transforming the treatment of fibrosis and inflammation-associated orphan diseases. The company is leveraging its differentiated endogenous nitrated fatty acid cell signaling technology platform, to focus on Focal Segmental Glomerulosclerosis (FSGS) and Pulmonary Arterial Hypertension (PAH). Complexa believes its approach has the ability to not only halt, but to reverse, disease related fibrosis. The company’s lead product CXA-10 is in Phase 2 trials.

Cortexyme is developing therapeutics based on a new theory of the cause of Alzheimer's and other degenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. Because the pathogen is persistent and resistant to broad spectrum antibiotics, Cortexyme has developed small molecules to stop disease progression.

Cydan is an orphan drug accelerator that identifies and de-risks programs with therapeutic and commercial potential. Cydan focuses on selecting promising assets with well understood biology and proof-of-concept data in animal models from academia, industry and other sources. Data generated during a rigorous de-risking process will enable formation of stand-alone companies and strategic partnerships.

CytomX Therapeutics is a clinical-stage biopharmaceutical company with a deep and differentiated oncology pipeline of investigational Probody™ therapeutics. Probody therapeutics are designed to exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. The Company’s pipeline includes proprietary cancer immunotherapies against clinically-validated targets, such as PD-L1, and first-in-class Probody drug conjugates against highly attractive targets, such as CD166 and CD71, which are considered to be inaccessible to conventional antibody drug conjugates due to their presence on healthy tissue.

DIR Technologies is a developer and manufacturer of inspection systems for the pharmaceutical and nutriceutical markets. The company has developed a suite of products that leverage thermal imaging, computer vision, and machine learning to provide in-line inspection of various manufacturing processes, such as induction sealing integrity and tablet/capsule bottle filling.

eFFECTOR is a clinical stage biopharmaceutical company pioneering the discovery and development of selective translation regulators as a new class of small molecule drugs for treating cancer. The company’s investigational compounds are designed to restore translational control to halt underlying disease mechanisms while preserving healthy physiological processes. eFFECTOR’s most advanced program focuses on the development of tomivosertib, which is in Phase 2 studies.

Epic Sciences is focused on developing novel diagnostics to improve and personalize the treatment and management of cancer. Epic was founded on a powerful platform to identify and characterize rare cells, including circulating tumor cells (CTCs).

G-Con designs and manufactures “PODs”, portable, self-contained cGMP facility modules that offer a cost-effective and flexible alternative to large, highly capitalized pharmaceutical manufacturing facilities with fixed equipment and limited flexibility.

Imara develops IMR-687, a preclinical phosphodiesterase-9 (PDE-9) inhibitor for sickle cell disease and other hemoglobinopathies. The company was granted exclusive global rights to Lundbeck's IMR687.

Kineta is a clinical stage biotechnology company with a mission to develop next generation immunotherapies that transform patients’ lives.

Kymera Therapeutics is pioneering a transformative new approach to treating previously untreatable diseases by advancing the field of targeted protein degradation, accessing the body’s innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Using its protein degradation platform, the company is building a therapeutic pipeline in oncology and immunology.

Lodo's genome-based, culture-independent platform combines DNA sequencing and bioinformatics to discover, synthesize, and characterize small-molecule therapeutics from natural microbial sources present in soil samples and the human microbiome. The company will initially focus on infectious diseases like tuberculosis, but also plans to pursue additional therapeutic areas including oncology, metabolic disorders, and rare diseases.

M2S is a pioneer and leader in imaging and data management technology. They were the first to develop and market 3-D imaging technology to vascular surgeons. Their Preview product is still the market leader in this field. In 2006, the company expanded into providing core lab services for clinical trials and customized data registries for physicians, hospitals, medical centers, and clinical researchers

Mangolia Neurosciences is a drug discovery and development company focused on the creation of a novel class of neuroprotective medicines. The company is focused on developing potent and highly selective neuroprotective therapies that have compelling preclinical pharmacologic profiles and for which clinical proof of concept can be obtained rapidly in order to address significant unmet patient needs.

Mersana Therapeutics is a clinical-stage biotechnology company with highly differentiated and proprietary antibody drug conjugate (ADC) platforms that allow for significantly higher drug loads, with the potential to provide greater efficacy while simultaneously increasing tolerability. The company’s lead product candidate, XMT1522, is in Phase I clinical trials and the second product candidate, XMT1536, will be entering clinical trials in early 2018. In addition, multiple partners are advancing their pipeline of ADCs using the Mersana platform.

Morphic Therapeutic is engaged in the discovery and development of a new generation of oral integrin drugs. Based on research conducted in the laboratory of the company’s founding scientist, Tim Springer, Morphic is advancing preclinical programs in autoimmunity, fibrosis, vascular disorders and immune-oncology.

NeuMoDx is developing a next generation testing platform for the in vitro molecular diagnostic (MDx) market. The product vision is to create a walk-away bench-top system that combines sensitivity, high speed (time to first result and throughput), low cost, and random access, in an “open” architecture that can support both IVDs and Lab Developed Tests (LDTs).

Focused on developing non-invasive therapies for psychiatric and neurological disorders using MRI-strength magnetic field pulses, Neuronetics is the first company to have a non-systemic and non-invasive depression treatment cleared by the FDA for patients who have not benefited from prior antidepressant treatment. Neuronetics is the leader in the development of NeuroStar TMS Therapy (transcranial magnetic stimulation), a non-invasive form of neuromodulation.

NextCure is discovering and developing first-in-class immunotherapy-based biologics for cancer and other diseases, building upon the work of its scientific founder, Dr. Lieping Chen. The company is focused on understanding novel tumor specific interactions and mechanisms of immune regulation at work in the tumor microenvironment to build a proprietary pipeline for mediating sustained immunity and improved outcomes for cancer patients.

Petra Pharma is a drug development company focused on novel enzyme targets that play a central role in a variety of important cellular processes, including cell division, growth, trafficking, and signaling. Petra Pharma will develop novel small molecules for the treatment of cancer and metabolic diseases to target these cellular processes in order to therapeutically impact human health.

Pyxis Oncology is building a differentiated portfolio of biologics, including antibody-drug conjugates (ADCs) and immunotherapies, to improve the lives of patients with difficult-to-treat cancers. Pyxis is employing site-specific conjugation technology to develop highly stable ADCs with superior therapeutic indexes. Pyxis is also advancing a diverse portfolio of immunotherapies.

Rhythm is a biopharmaceutical company developing peptide therapeutics that address unmet needs in metabolic diseases: RM-493, a small-peptide melanocortin-4 receptor (MC4R) agonist, for the treatment of obesity and diabetes; and RM-131, a small-peptide ghrelin agonist, for the treatment of diabetic gastroparesis. RM-131 was acquired by Allergan.

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company that applies a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from severe rare diseases and cancer. The company launched in 2017 with a portfolio of clinically validated therapies in-licensed from Pfizer.

System1 employs phenotypic screening to discover novel drugs for complex neurological and psychiatric diseases for which current discovery techniques have proved least successful. System1 combines cerebral organoid science, systems neuroscience, robotic automation, and advanced data analytics to discover characterizations of disease never before achievable. These “deep phenotypes” are exploited to identify novel therapeutic targets and drug treatments.

TetraLogic is a biopharmaceutical company developing novel, targeted drugs to treat cancer. The company’s Smac-mimetic candidates regulate the apoptosis (programmed cell death) pathway by unblocking the pathway to kill cancer cells. IPO 2013. Assets sold to Medivir in Dec 2016.

Translate Bio is developing a new class of therapeutics made of messenger RNA (mRNA), designed to enable in vivo production of intracellular, membrane-associated and secreted proteins. Delivering mRNAs enables a patient's own cells to produce the proteins needed to treat or prevent diseases that cannot be addressed with current technologies.

Triplet Therapeutics is a biotechnology company harnessing human genetics to develop treatments for repeat expansion disorders at their source. Triplet is developing RNA therapeutics to precisely knock down key components of the DDR pathway that drive repeat expansion across a wide range of disorders.

VectivBio is a spin out of Therachon (acquired by Pfizer in 2019), that will focus on conditions caused by well understood molecular alterations that can be targeted with transformational therapeutics. The lead product candidate is apraglutide, a next-generation, synthetic GLP-2 analog that has undergone extensive preclinical characterization and optimization as well as early clinical testing. It is being developed as a potential best-in-class therapeutic for the treatment of short bowel syndrome.

Yumanity Therapeutics proprietary platforms have identified previously unknown disease targets that when modulated can correct the cellular toxicities created by misfolded proteins. Beyond advancing the lead program that corrects toxicity associated with α-synuclein, a protein linked to Parkinson’s disease, the company is also identifying compounds for Alzheimer’s disease and ALS.

We are a public benefit corporation whose mission is to displace the petrochemicals that pollute the Planet by designing, developing, and commercializing bio-based materials that deliver better performance than existing products, at attractive costs